Shots:

• The US FDA has granted ODD to CFT7455 for the treatment of MM. The FDA grants ODD to drugs & biologics that are intended for the safe and effective treatment- diagnosis or prevention of rare diseases- or conditions that affect fewer than 200-000 people in the US
• In Jun’21- the company has initiated a P-I/II clinical trial to evaluates safety- tolerability- and anti-tumor activity of CFT7455 in ~160 patients with secondary and exploratory objectives are to identify the PK and PD of the therapy
• CFT7455 (PO) is a bioavailable MonoDAC degrader targeting IKZF1/3 for the treatment of MM and NHL including peripheral T-cell lymphoma and MCL

  | Ref: C4 Therapeutics | Image: Analyze Markets